Literature DB >> 10807077

Hereditary ataxias.

V G Evidente1, K A Gwinn-Hardy, J N Caviness, S Gilman.   

Abstract

There are many causes of hereditary ataxia. These can be grouped into categories of autosomal recessive, autosomal dominant, and X-linked. Molecularly, many of them are due to trinucleotide repeat expansions. In Friedreich ataxia, the trinucleotide repeat expansions lead to a "loss of function." In the dominant ataxias, the expanded repeats lead to a "gain of function," most likely through accumulation of intranuclear (and less commonly cytoplasmic) polyglutamine inclusions. Channelopathies can also lead to ataxia, especially episodic ataxia. Although phenotypic characteristics are an aid to the clinician, a definitive diagnosis is usually made only through genotypic or molecular studies. Genetic counseling is necessary for the testing of symptomatic and asymptomatic individuals. No effective treatment is yet available for most ataxic syndromes, except for ataxia with isolated vitamin E deficiency and the episodic ataxias.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807077     DOI: 10.4065/75.5.475

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  11 in total

1.  Learning cell biology as a team: a project-based approach to upper-division cell biology.

Authors:  Robin Wright; James Boggs
Journal:  Cell Biol Educ       Date:  2002

2.  Spinocerebellar ataxia type 4 (SCA4): Initial pathoanatomical study reveals widespread cerebellar and brainstem degeneration.

Authors:  Y Hellenbroich; K Gierga; E Reusche; E Schwinger; T Deller; R A I de Vos; C Zühlke; U Rüb
Journal:  J Neural Transm (Vienna)       Date:  2005-12-19       Impact factor: 3.575

3.  Gait and Balance Dysfunction in Adults.

Authors:  Salil Manek; Mark F. Lew
Journal:  Curr Treat Options Neurol       Date:  2003-03       Impact factor: 3.598

4.  Spinocerebellar ataxias types 2 and 3: degeneration of the pre-cerebellar nuclei isolates the three phylogenetically defined regions of the cerebellum.

Authors:  U Rüb; K Gierga; E R Brunt; R A I de Vos; M Bauer; L Schöls; K Bürk; G Auburger; J Bohl; C Schultz; M Vuksic; G J Burbach; H Braak; T Deller
Journal:  J Neural Transm (Vienna)       Date:  2005-03-23       Impact factor: 3.575

5.  Absence of aprataxin gene mutations in a Greek cohort with sporadic early onset ataxia and normal GAA triplets in frataxin gene.

Authors:  C Daiou; K Christodoulou; G Xiromerisiou; M Panas; E Dardiotis; A Kladi; M Speletas; G Ntaios; A Papadimitriou; A Germenis; Georgios M Hadjigeorgiou
Journal:  Neurol Sci       Date:  2009-12-02       Impact factor: 3.307

6.  Population based study of late onset cerebellar ataxia in south east Wales.

Authors:  M B Muzaimi; J Thomas; S Palmer-Smith; L Rosser; P S Harper; C M Wiles; D Ravine; N P Robertson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

7.  Ataxin-3 interactions with rad23 and valosin-containing protein and its associations with ubiquitin chains and the proteasome are consistent with a role in ubiquitin-mediated proteolysis.

Authors:  Ellen W Doss-Pepe; Edward S Stenroos; William G Johnson; Kiran Madura
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

8.  Prevalence rate and functional status of cerebellar ataxia in Korea.

Authors:  Byung-Euk Joo; Chan-Nyoung Lee; Kun-Woo Park
Journal:  Cerebellum       Date:  2012-09       Impact factor: 3.847

9.  Tensor-based morphometry and stereology reveal brain pathology in the complexin1 knockout mouse.

Authors:  Catherine Kielar; Stephen J Sawiak; Paloma Navarro Negredo; Desmond H Y Tse; A Jennifer Morton
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

10.  Sodium valproate alleviates neurodegeneration in SCA3/MJD via suppressing apoptosis and rescuing the hypoacetylation levels of histone H3 and H4.

Authors:  Jiping Yi; Li Zhang; Beisha Tang; Weiwei Han; Yafang Zhou; Zhao Chen; Dandan Jia; Hong Jiang
Journal:  PLoS One       Date:  2013-01-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.